Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Pacific Biosciences of California Q3 2026 Results: Net Loss of $37.8M, Loss Narrows

Pacific Biosciences reported total revenue of $40.6 million for Q3 2026, a slight increase from $38.4 million in the prior year. The company recorded a net loss of $37.8 million for the quarter, showing improvement over the $506.0 million net loss in the nine-month period of 2025 which was heavily impacted by significant intangible asset amortization and impairment charges.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue40.638.4
Gross profit13.515.9
Profit before tax-37.6-37.6
Net income-37.8-38.0
EPS (diluted, $ a share)$-0.12$-0.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+5.5%
Gross margin33.2%
Operating margin-91.2%
Source

10-Q filed with the SEC, NASDAQ: PACB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pacific Biosciences of California, Inc.: key numbers

Share price
$1.84Close, Nov 16
Market cap
$576M
Shares outstanding
312.93MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pacific Biosciences of California, Inc.

All →
4:08 PM ET 8-K
Capital Raise

Pacific Biosciences of California Capital Raise

Pacific Biosciences of California entered into a sales agreement with Allen & Company LLC to establish an at-the-market (ATM) equity offering program. The company may sell up to $100 million of its common stock from time to time at its discretion. Allen & Company will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds.

Counterparty
Allen & Company LLC
4:11 PM ET 8-K
Financial Results

Pacific Biosciences of California Financial Results

Pacific Biosciences reported Q3 2026 revenue of $40.6 million, driven by demand for its Revio and Vega sequencing systems. Alongside the results, the company announced that CFO Jim Gibson has stepped down and transitioned to an advisory role, with CEO Mark Van Oene serving as interim CFO during a search for a permanent successor.

Term
Q3 2026

“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”

Mark Van Oene, President and Chief Executive Officer
4:08 PM ET Form 4
Insider Selling

Pacific Biosciences of California Insider James R. Gibson II Sells $2.06M of Stock

James R. Gibson II sold 661,815 shares of Pacific Biosciences of California, Inc. at $3.11 a share, worth $2.06M in total on Oct 6, 2026. Shares held after the trade: 1,083,848 (-37.9%).

Value
$2.06M
Shares
661,815
Price
$3.11
Holding change
-37.9%
Trade date
Oct 6, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.